Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 3/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321979 | 0.86 | KIF11 (0.53) | KYNUKIF11ACP3 | |
| SCHEMBL27644152 | 0.85 | KYNU (0.48) | KYNUKIF11GRM2GRM3ACP3 | |
| SCHEMBL6255681 | 0.83 | GRM2 (0.61) | KYNUGRM2GRM3SLC7A5SLC1A3 | |
| SCHEMBL5325189 | 0.83 | GRM2 (0.61) | KYNUGRM2GRM3SLC7A5SLC1A3 | |
| SCHEMBL5924700 | 0.83 | GRM2 (0.61) | KYNUGRM2GRM3SLC7A5SLC1A3 | |
| SCHEMBL18886173 | 0.83 | GRM2 (0.61) | KYNUGRM2GRM3SLC7A5SLC1A3 | |
| SCHEMBL5924823 | 0.83 | GRM2 (0.61) | KYNUGRM2GRM3SLC7A5SLC1A3 | |
| SCHEMBL5319551 | 0.83 | KYNU (0.49) | KYNUKIF11GRM2GRM3ACP3 | |
| SCHEMBL4988045 | 0.82 | ACP3 (0.41) | KIF11GRM2GRM3ACP3AKR1C3 | |
| Hydrochloric Acid SCHEMBL10792123 | 0.82 | GRM2 (0.59) | KYNUGRM2GRM3SLC7A5SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | KYNU 1045/4885KIF11 1678/4885GRM2 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.